US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 11:01:50 Source:opinionsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Congo names third American in a foiled coup plot as mourners gather in Utah to remember plot leader
Next:Haiti’s international airport reopens after gang violence
You may also like
- Adela Cernousek of Texas A&M wins NCAA individual golf title for first collegiate win
- OnlyFans model Ava Louise who flashed her breasts at the New York
- The Latest
- Double Dutch! Chaotic European
- A Canadian serial killer who brought victims to a pig farm is hospitalized after a prison assault
- Florida deputy's killing of Black airman renews debate on police killings and race
- Maverick Kentucky congressman has avoided fallout at home after antagonizing GOP leaders
- Russell Wilson and Ciara 'close sale of Seattle mansion, raking in $31M for six
- PHOTOS: At the Pet Gala, fashion goes to the dogs